Ֆուրազոլիդոն

main_info

  • trade_name:
  • Ֆուրազոլիդոն
  • dosage:
  • 50մգ(10) ստրիպում
  • pharmaceutical_form:
  • դեղահատեր
  • prescription_type:
  • Դեղատոմսով
  • medicine_domain:
  • Human
  • medicine_type:
  • Allopathic

documents

localization

  • country:
  • Ֆուրազոլիդոն
    አርሜኒያ
  • language:
  • አማርኛ

other_info

status

  • source:
  • Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում - Armenia
  • last_update:
  • 31-05-2018

6-4-2019

Outcome of the public consultation on the draft guidance on the assessment of the safety of feed additives for the environment

Outcome of the public consultation on the draft guidance on the assessment of the safety of feed additives for the environment

Published on: Fri, 05 Apr 2019 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on the draft guidance on the assessment of the safety of feed additives for the environment prepared by the EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP) and endorsed by the Panel for public consultation at its Plenary meeting on 2 October 2018. The written public consultation for this docume...

Europe - EFSA - European Food Safety Authority EFSA Journal

3-4-2019


Paediatric Committee (PDCO): 26 February-1 March 2019, European Medicines Agency, from 26/02/2019 to 01/03/2019

Paediatric Committee (PDCO): 26 February-1 March 2019, European Medicines Agency, from 26/02/2019 to 01/03/2019

Paediatric Committee (PDCO): 26 February-1 March 2019, European Medicines Agency, from 26/02/2019 to 01/03/2019

Europe - EMA - European Medicines Agency

26-3-2019

Technical report of the public consultation on the draft ‘Guidance on harmonised risk assessment methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals’

Technical report of the public consultation on the draft ‘Guidance on harmonised risk assessment methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals’

Published on: Mon, 25 Mar 2019 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on the draft guidance of the working group of the Scientific Committee ‘Harmonised risk assessment methodologies for human health, animal health and ecological risk assessment of combined exposure to multiple chemicals’. The background and the Terms of Reference were prepared by EFSA staff and the working group of the Scienti...

Europe - EFSA - European Food Safety Authority EFSA Journal

13-3-2019

Multi-country outbreak of Salmonella Poona infections linked to consumption of infant formula

Multi-country outbreak of Salmonella Poona infections linked to consumption of infant formula

Published on: Tue, 12 Mar 2019 An outbreak of 32 Salmonella enterica serotype Poona cases in infants and young children has recently been identified in France (30 cases), Belgium (one case) and Luxembourg (one case). All 32 patients were infected with the same bacterial strain based on core genome multilocus sequence typing analysis. All patients had onset of symptoms between August 2018 and February 2019. Information from interviews was available for 30 patients. All consumed one of three rice-based in...

Europe - EFSA - European Food Safety Authority EFSA Journal

12-3-2019


Agenda - CAT agenda of the 20-22 February 2019 meeting

Agenda - CAT agenda of the 20-22 February 2019 meeting

Agenda - CAT agenda of the 20-22 February 2019 meeting

Europe - EMA - European Medicines Agency

27-2-2019

Schell returns to FDA to lead Surveillance and Compliance for CVM

Schell returns to FDA to lead Surveillance and Compliance for CVM

The FDA announced today that Timothy Schell, Ph.D., has returned to the agency’s Center for Veterinary Medicine to lead its Office of Surveillance and Compliance. Dr. Schell rejoined the agency on February 17, 2019.

FDA - U.S. Food and Drug Administration

27-2-2019

Enforcement Report for the Week of February 27, 2019

Enforcement Report for the Week of February 27, 2019

Recently Updated Records for the Week of February 27, 2019 Last Modified Date: Wednesday, February 20, 2019

FDA - U.S. Food and Drug Administration

25-2-2019

February 22, 2019: Lehigh Valley Technologies, Inc. to Pay $4 Million to Resolve False Claims Act Liability for Scheme to Avoid FDA New Drug Application Fee

February 22, 2019: Lehigh Valley Technologies, Inc. to Pay $4 Million to Resolve False Claims Act Liability for Scheme to Avoid FDA New Drug Application Fee

February 22, 2019: Lehigh Valley Technologies, Inc. to Pay $4 Million to Resolve False Claims Act Liability for Scheme to Avoid FDA New Drug Application Fee

FDA - U.S. Food and Drug Administration

22-2-2019

February 20, 2019: Home Health Nurse Sentenced to Federal Prison for Tampering with Patients' Medication

February 20, 2019: Home Health Nurse Sentenced to Federal Prison for Tampering with Patients' Medication

February 20, 2019: Home Health Nurse Sentenced to Federal Prison for Tampering with Patients' Medication

FDA - U.S. Food and Drug Administration

22-2-2019

Enforcement Report for the Week of February 20, 2019

Enforcement Report for the Week of February 20, 2019

Recently Updated Records for the Week of February 20, 2019 Last Modified Date: Friday, February 22, 2019

FDA - U.S. Food and Drug Administration

22-2-2019

Enforcement Report for the Week of January 23, 2019

Enforcement Report for the Week of January 23, 2019

Recently Updated Records for the Week of January 23, 2019 Last Modified Date: Friday, February 22, 2019

FDA - U.S. Food and Drug Administration

21-2-2019

February 21, 2019: Traveling Nurse Who Worked in Roanoke Sentenced for Tampering with Fentanyl

February 21, 2019: Traveling Nurse Who Worked in Roanoke Sentenced for Tampering with Fentanyl

February 21, 2019: Traveling Nurse Who Worked in Roanoke Sentenced for Tampering with Fentanyl

FDA - U.S. Food and Drug Administration

20-2-2019


Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Committee for Medicinal Products for Veterinary Use (CVMP): 19-21 February 2019, European Medicines Agency, from 19/02/2019 to 21/02/2019

Europe - EMA - European Medicines Agency

19-2-2019

February 15, 2019: Participant in Fraudulent Opioid Prescription Conspiracy Sentenced

February 15, 2019: Participant in Fraudulent Opioid Prescription Conspiracy Sentenced

February 15, 2019: Participant in Fraudulent Opioid Prescription Conspiracy Sentenced

FDA - U.S. Food and Drug Administration

19-2-2019

Chukar Cherries Expands Recall Of Amaretto Rainier Ultra Dark Chocolate Cherries Pouches Due To Undeclared Milk

Chukar Cherries Expands Recall Of Amaretto Rainier Ultra Dark Chocolate Cherries Pouches Due To Undeclared Milk

February 18, 2019, Chukar Cherries of Prosser, WA is recalling 7.5oz Amaretto Rainier Ultra Dark Chocolate Cherries because they may contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume this product.

FDA - U.S. Food and Drug Administration

13-2-2019

Enforcement Report for the Week of February 13, 2019

Enforcement Report for the Week of February 13, 2019

Recently Updated Records for the Week of February 13, 2019 Last Modified Date: Monday, February 11, 2019

FDA - U.S. Food and Drug Administration

12-2-2019

February 7, 2019: Three Federal Cases Allege Illegal Importation and Sale of ‘Herbal’ Sexual Enhancement Pills that Contained Pharmaceutical Drugs

February 7, 2019: Three Federal Cases Allege Illegal Importation and Sale of ‘Herbal’ Sexual Enhancement Pills that Contained Pharmaceutical Drugs

February 7, 2019: Three Federal Cases Allege Illegal Importation and Sale of ‘Herbal’ Sexual Enhancement Pills that Contained Pharmaceutical Drugs

FDA - U.S. Food and Drug Administration

11-2-2019


Agenda - PRAC draft agenda of meeting 11-14 February 2019

Agenda - PRAC draft agenda of meeting 11-14 February 2019

Agenda - PRAC draft agenda of meeting 11-14 February 2019

Europe - EMA - European Medicines Agency

6-2-2019

Enforcement Report for the Week of February 06, 2019

Enforcement Report for the Week of February 06, 2019

Recently Updated Records for the Week of February 06, 2019 Last Modified Date: Tuesday, February 05, 2019

FDA - U.S. Food and Drug Administration

6-2-2019

ANSES Newsletter in English - N°51 - February 2019

ANSES Newsletter in English - N°51 - February 2019

France - Agence Nationale du Médicament Vétérinaire

30-1-2019

Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee

Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee

February 12, 2019: Joint Meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management (DSaRM) Advisory Committee

FDA - U.S. Food and Drug Administration

24-10-2018

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, LLC is Expanding Recall to Include All Product Lots Manufactured from February 27, 2018 Through July 20, 2018, Because of Possible Listeria Monocytogenes Health Risk

G & C Raw, of Versailles, OH is recalling all products lots manufactured from February 27, 2018 through July 20, 2018, as a precaution because they have the potential to be contaminated with Listeria monocytogenes

FDA - U.S. Food and Drug Administration

22-9-2018

Risk assessment of new sequencing information for genetically modified soybean BPS‐CV127‐9

Risk assessment of new sequencing information for genetically modified soybean BPS‐CV127‐9

Published on: Fri, 21 Sep 2018 00:00:00 +0200 The GMO Panel has previously assessed genetically modified (GM) soybean BPS‐CV127‐9. This soybean was found to be as safe and nutritious as its conventional counterpart and commercial soybean varieties with respect to potential effects on human and animal health and the environment in the context of its intended uses. On 16 February 2018, European Commission requested EFSA to analyse new nucleic acid sequencing data and updated bioinformatics data for GM soy...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Outcome of the public consultation on a draft protocol for the Scientific Opinion on dietary sugars

Outcome of the public consultation on a draft protocol for the Scientific Opinion on dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) carried out a public consultation to receive input from the scientific community and all interested parties on a draft protocol for the Scientific Opinion on free sugars from all dietary sources, prepared by the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel), supported by the ad‐hoc Working Group on Sugars. The draft protocol was endorsed by the Panel for public consultation at its plenary meeti...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Protocol for the scientific opinion on the Tolerable Upper Intake Level of dietary sugars

Published on: Fri, 10 Aug 2018 00:00:00 +0200 In June 2016, EFSA received a mandate from the national food competent authorities of five European countries (Denmark, Finland, Iceland, Norway and Sweden) to provide a dietary reference value (DRV) for sugars, with particular attention to added sugars. A draft protocol was developed with the aim of defining as much as possible beforehand the strategy that will be applied for collecting data, appraising the relevant evidence, and analysing and integrating t...

Europe - EFSA - European Food Safety Authority Publications

30-7-2018

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

Under the national nutrivigilance scheme, reports of adverse effects likely to be associated with the consumption of food supplements containing melatonin have been brought to the attention of ANSES. A retrospective analysis of these reports, combined with the considerable level of consumption of this type of supplement, led ANSES to conduct an assessment of the potential health risks. In its Opinion of February 2018, the Agency highlighted the existence of populations and situations at risk, for which t...

France - Agence Nationale du Médicament Vétérinaire

1-6-2018

SunMed Holdings, LLC Issues a Nationwide Recall of STAT-Check and Medline Manual Resuscitator Bags

SunMed Holdings, LLC Issues a Nationwide Recall of STAT-Check and Medline Manual Resuscitator Bags

On May 29, 2018, SunMed Holdings, LLC initiated a nationwide recall of 18,808 units of STAT-Check and Medline resuscitator bags which were distributed between February 1, 2018 to May 13, 2018. The patient port retaining ring of the affected bags may not fully seat which may allow the patient port to detach during use. If this takes place, the resuscitator bags may not deliver air to the patient and result in a delay in treatment and life-threatening health consequences. There have been no reported injuri...

FDA - U.S. Food and Drug Administration

25-5-2018

Orphan designation:  Treprostinil sodium,  for the: Treatment of chronic thromboembolic pulmonary hypertension

Orphan designation: Treprostinil sodium, for the: Treatment of chronic thromboembolic pulmonary hypertension

On 8 February 2013, orphan designation (EU/3/13/1103) was granted by the European Commission to SciPharm S.a.r.L, Luxembourg, for treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension.

Europe - EMA - European Medicines Agency

1-3-2018

All marketing authorisation letters are now sent electronically to Danish companies

All marketing authorisation letters are now sent electronically to Danish companies

On 20 February 2018, the Danish Medicines Agency extended its use of digital post and now sends all letters, and not just decisions, about marketing authorisations electronically to Danish companies.

Danish Medicines Agency

6-3-2017

Danish Pharmacovigilance Update, February 2017

Danish Pharmacovigilance Update, February 2017

The February issue of Danish Pharmacovigilance Update.

Danish Medicines Agency

31-1-2017

We are extending our opening hours

We are extending our opening hours

From Wednesday 1 February 2017, we are extending our opening hours. This means that the reception will be open Monday to Friday from 8.30am to 3.30pm. You can also call us on our main telephone number during these hours.

Danish Medicines Agency

9-3-2016

Danish Pharmacovigilance Update, February 2016

Danish Pharmacovigilance Update, February 2016

The February issue of Danish Pharmacovigilance Update with news from the EU, the DKMA and short news.

Danish Medicines Agency

16-3-2015

Danish Pharmacovigilance Update, February 2015

Danish Pharmacovigilance Update, February 2015

The February issue of Danish Pharmacovigilance Update with news from the EU, the DHMA and short news.

Danish Medicines Agency

3-2-2015

New director at the DHMA

New director at the DHMA

On 1 February 2015, Anne-Marie Vangsted, Acting Head of Division, took up the position as Director with responsibility for supervision at the Danish Health and Medicines Authority. The new position as director was created as part of our action plan aimed at modernising the supervisory function, in which Anne-Marie Vangsted has played a key role since we presented the plan on 15 September 2014.

Danish Medicines Agency

21-1-2015

Consultation on transparency in clinical trials

Consultation on transparency in clinical trials

The European Medicines Agency (EMA) has launched a public consultation on how to implement the transparency requirements of the new EU Clinical Trials Regulation. Deadline on 18 February.

Danish Medicines Agency

1-4-2014

Danish Pharmacovigilance Update 27 February 2014

Danish Pharmacovigilance Update 27 February 2014

In this issue of Danish Pharmacovigilance Update: Further restrictions on the use of osteoporosis medicine strontium ranelate (Protelos®), Anticoagulant therapy to be stopped before initiating treatment with the new oral anticoagulants (NOACs).

Danish Medicines Agency

25-4-2013

Danish Pharmacovigilance Update, 21 February 2013

Danish Pharmacovigilance Update, 21 February 2013

In this issue of Danish Pharmacovigilance Update: Cardiovascular monitoring when initiating and re-initiating treatment with fingolimod (Gilenya®).

Danish Medicines Agency

5-3-2012

Danish Pharmacovigilance Update, 16 February 2012

Danish Pharmacovigilance Update, 16 February 2012

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Risk of overdose with methotrexate in the treatment of rheumatoid arthritis as well as intensified monitoring of heart rate and blood pressure in connection with treatment with Gilenya.

Danish Medicines Agency

4-4-2019

TGA webinar presentation: 7 February 2019

TGA webinar presentation: 7 February 2019

This presentation discusses where the TGA fits in the broader digital health environment.

Therapeutic Goods Administration - Australia

6-3-2019


CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2019

CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2019

CAT monthly report of application procedures, guidelines and related documents on advanced therapies: February 2019

Europe - EMA - European Medicines Agency

26-2-2019

TGA presentation: Stakeholder Workshop held in TGA, Symonston, 8 February 2019

TGA presentation: Stakeholder Workshop held in TGA, Symonston, 8 February 2019

This presentation highlights some of the concerns related to system or procedure pack medical devices.

Therapeutic Goods Administration - Australia

22-2-2019


Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Committee for Medicinal Products for Veterinary Use (CVMP) meeting of 19-21 February 2019

Europe - EMA - European Medicines Agency

15-2-2019

#ICYMI: On February 14th, @US_FDA identified a Class I Recall, the most serious type of recall: Medtronic, Inc. Recalls Dual Chamber Implantable Pulse Generators (IPGs) Due to Possible Circuit Error. Find out more about the recall:  https://go.usa.gov/xEU

#ICYMI: On February 14th, @US_FDA identified a Class I Recall, the most serious type of recall: Medtronic, Inc. Recalls Dual Chamber Implantable Pulse Generators (IPGs) Due to Possible Circuit Error. Find out more about the recall: https://go.usa.gov/xEU

#ICYMI: On February 14th, @US_FDA identified a Class I Recall, the most serious type of recall: Medtronic, Inc. Recalls Dual Chamber Implantable Pulse Generators (IPGs) Due to Possible Circuit Error. Find out more about the recall: https://go.usa.gov/xEUhq  #MedicalDevice #FDA pic.twitter.com/YNkrpGSOhH

FDA - U.S. Food and Drug Administration

15-2-2019


Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 11-14 February 2019

Europe - EMA - European Medicines Agency

15-2-2019

Upcoming changes to permissible indications for listed medicines

Upcoming changes to permissible indications for listed medicines

Subject to the approval of the Delegate of the Minister of Health, this page outlines changes that will be made to the Therapeutic Goods (Permissible Indications) Determination No. 1 of 2018 in February 2019

Therapeutic Goods Administration - Australia

13-2-2019


Human medicines highlights - February 2019

Human medicines highlights - February 2019

Human medicines highlights - February 2019

Europe - EMA - European Medicines Agency

8-2-2019

On February 5th, @US_FDA identified a Class I Recall, the most serious type of recall: Edwards Lifesciences Recalls Swan-Ganz Thermodilution Catheter Due to Incorrect Assembly Causing Reversal of Lumens. Find out more about the recall:  https://go.usa.gov

On February 5th, @US_FDA identified a Class I Recall, the most serious type of recall: Edwards Lifesciences Recalls Swan-Ganz Thermodilution Catheter Due to Incorrect Assembly Causing Reversal of Lumens. Find out more about the recall: https://go.usa.gov

On February 5th, @US_FDA identified a Class I Recall, the most serious type of recall: Edwards Lifesciences Recalls Swan-Ganz Thermodilution Catheter Due to Incorrect Assembly Causing Reversal of Lumens. Find out more about the recall: https://go.usa.gov/xER5f  #FDA #MedicalDevice pic.twitter.com/6adzC2txTv

FDA - U.S. Food and Drug Administration

8-2-2019

On February 4th, @US_FDA  identified a Class I Recall, the most serious type of recall: Medex Cardio-Pulmonary, recalls sterile saline and  sterile water for inhalation due to potential exposure to infectious agents as a result of leaking containers:  htt

On February 4th, @US_FDA identified a Class I Recall, the most serious type of recall: Medex Cardio-Pulmonary, recalls sterile saline and sterile water for inhalation due to potential exposure to infectious agents as a result of leaking containers: htt

On February 4th, @US_FDA identified a Class I Recall, the most serious type of recall: Medex Cardio-Pulmonary, recalls sterile saline and sterile water for inhalation due to potential exposure to infectious agents as a result of leaking containers: https://go.usa.gov/xER5V  pic.twitter.com/J0onEcDwqE

FDA - U.S. Food and Drug Administration

7-2-2019

Publication of interim decisions amending, or not amending, the current Poisons Standard, February 2019

Publication of interim decisions amending, or not amending, the current Poisons Standard, February 2019

Interim decisions and invitation for further comment. Closing date: 7 March 2019

Therapeutic Goods Administration - Australia

4-2-2019

On February 1st, @US_FDA classified a Class I Recall, the most serious   type of recall: Terrific Care, LLC. / Medex Supply Recalls CoaguChek XS  PT Test Strips Used to Monitor Blood Thinner Warfarin Due to Inaccurate  Test Results. Find out more here:  h

On February 1st, @US_FDA classified a Class I Recall, the most serious type of recall: Terrific Care, LLC. / Medex Supply Recalls CoaguChek XS PT Test Strips Used to Monitor Blood Thinner Warfarin Due to Inaccurate Test Results. Find out more here: h

On February 1st, @US_FDA classified a Class I Recall, the most serious type of recall: Terrific Care, LLC. / Medex Supply Recalls CoaguChek XS PT Test Strips Used to Monitor Blood Thinner Warfarin Due to Inaccurate Test Results. Find out more here: https://go.usa.gov/xEX7Y  pic.twitter.com/MeFubksqsa

FDA - U.S. Food and Drug Administration

11-1-2019

Consultation: Good Clinical Practice Inspections Program

Consultation: Good Clinical Practice Inspections Program

The TGA is seeking comments from interested parties on a pilot Good Clinical Practice (GCP) Inspections Program of 12 months duration that will inform a routine GCP Inspections Program. Closing date: 22 February 2019

Therapeutic Goods Administration - Australia

9-1-2019

Consultation: Proposed amendments to the Poisons Standard - ACCS meeting, March 2019

Consultation: Proposed amendments to the Poisons Standard - ACCS meeting, March 2019

Invitation to comment on proposed amendments to the Poisons Standard - ACCS, March 2019 (late addition to the published agenda). Closing date: 8 February 2019

Therapeutic Goods Administration - Australia

7-1-2019

Consultation: Changes to a number of definitions and the scope of the medical device regulatory framework in Australia

Consultation: Changes to a number of definitions and the scope of the medical device regulatory framework in Australia

The TGA is seeking your comments on the proposal to introduce new and amended definitions, and a revised scope of the products regulated as medical devices in Australia. Closing date: 18 February 2019

Therapeutic Goods Administration - Australia

7-1-2019

Consultation: Potential reclassification of active medical devices for diagnosis and patient therapy

Consultation: Potential reclassification of active medical devices for diagnosis and patient therapy

The TGA seeks comments on the extent to which a similar approach will be appropriate in the Australian regulatory context. Closing date: 18 February 2019

Therapeutic Goods Administration - Australia

7-1-2019

Consultation: Proposal to introduce a Unique Device Identification (UDI) system for medical devices in Australia

Consultation: Proposal to introduce a Unique Device Identification (UDI) system for medical devices in Australia

We seek your views on the proposed regulatory changes that would facilitate the adoption of the internationally harmonised principles for introduction of the UDI system in Australia. Closing date: 18 February 2019

Therapeutic Goods Administration - Australia

21-12-2018

Consultation: Fees and charges proposal 2019-20

Consultation: Fees and charges proposal 2019-20

The TGA is seeking comments from interested parties on the proposed changes in fees and charges for 2019-2020. Closing date: 8 February 2018

Therapeutic Goods Administration - Australia

20-12-2018

Review of the Narcotic Drugs Act 1967 - Public meetings

Review of the Narcotic Drugs Act 1967 - Public meetings

The TGA will be hosting public meetings in February 2019 in Sydney, Brisbane and Melbourne

Therapeutic Goods Administration - Australia

19-12-2018

Consultation: Medical device cyber security

Consultation: Medical device cyber security

The TGA is seeking comments from interested parties on the applicability and usefulness of the content contained in the draft regulatory guidance and information materials. Closing date: 14 February 2019

Therapeutic Goods Administration - Australia

18-12-2018

Consultation: Review of Therapeutic Goods Order 54 - Standards for Disinfectants; and associated guidance

Consultation: Review of Therapeutic Goods Order 54 - Standards for Disinfectants; and associated guidance

TGA is seeking comments on the expansion and amendment of TGO 54. Closing date: 12 February 2019

Therapeutic Goods Administration - Australia

17-12-2018

Consultation: Remaking Therapeutic Goods Order No. 78

Consultation: Remaking Therapeutic Goods Order No. 78

A consultation on the remaking of Therapeutic Goods Order No 78 has been released. Have your say! Closing date: 8 February 2019

Therapeutic Goods Administration - Australia

25-5-2018

ACV meeting statement, Meeting 6, 7 February 2018

ACV meeting statement, Meeting 6, 7 February 2018

Advisory Committee on Vaccines meeting statement

Therapeutic Goods Administration - Australia

16-5-2018

 Minutes - PDCO minutes of the 20-23 February 2018 meeting

Minutes - PDCO minutes of the 20-23 February 2018 meeting

Europe - EMA - European Medicines Agency

15-5-2018

 Minutes of the COMP meeting of 13-15 February 2018

Minutes of the COMP meeting of 13-15 February 2018

Europe - EMA - European Medicines Agency

2-5-2018

 Minutes of the CAT meeting 15-16 February 2018

Minutes of the CAT meeting 15-16 February 2018

Europe - EMA - European Medicines Agency